FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286295054> ?p ?o ?g. }

• W4286295054 endingPage "3509" @default.
• W4286295054 startingPage "3509" @default.
• W4286295054 abstract "3509 Background: FOLFOXIRI plus bevacizumab (BEV) represents standard chemotherapy in first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC). The NIVACOR study evaluates the addition of nivolumab (NIV) to FOLFOXIRI/BEV as first-line therapy in mCRC RAS/BRAF mut pts regardless of MSS/MSI status. Methods: This is a single-arm, multicenter, open-label, phase II trial in first-line treatment of pts with mCRC RAS/BRAF mut. Pts received NIV at a flat dose of 240 mg q14 days, FOLFOXIRI (irinotecan 165 mg/m 2 , oxaliplatin 85 mg/m 2 , leucovorin 200 mg/m 2 , and 5-fluorouracil CI 3,200 mg/m 2 for 48 hours) in combination with BEV at the dose of 5 mg/kg IV q14 days for eight cycles and then, the maintenance with BEV/NIV until PD or unacceptable toxicities. The primary endpoint was the ORR according to RECIST 1.1 Criteria. All images are reviewed by Independent Data Monitoring Committee. According to Fleming’s design with alpha and beta levels of 0.05 and 0.2 respectively, in a sample size of 73 pts (comprehensive of a 10% drop-out rate), at least 56 responses were necessary to not reject the alternative hypothesis of an ORR=0.80. Results: From October 2019 to March 2021, 73 pts were enrolled in 9 Italian centers. The median age was 60 (51-65) years and 50.7% were male; the main primary tumor side was right (50.7%). The molecular characterization was: 87.7% RAS mut, 16.2% BRAF mut, and 4.5% both RAS and BRAF mut; 10/62 were MSI (16.1%), 52/62 (83.9%) MSS, and 11 pts not assessed. Liver metastases were present in 56.2% pts. The median follow-up was 14.3 (IQR 11.5-16.5) months on December 31, 2021. The median (m) duration of treatment was 12 (8-17) cycles. The ORR was 76.7%, with 7(9.6%) CR and 49(67.1%) PR. SD were 15(20.6%) with a DCR of 97.3%; 2(2.7%) pts were not evaluable. The mDOR was 8.4 (95%CI, 7-NE) months. The mPFS was 10.1 months (95%CI, 9.4-NE) and 12-months PFS was 53.4%. At data cut-off, 65 (89.1%) pts are still alive. In subgroups analysis of MSS pts the ORR was 78.9% with a mDOR of 7.59 (95% CI 6.21 -11.43) months, DCR of 96.2%, and mPFS of 9.8 (95%CI 8.18-15.24) months. The surgery of the primary tumor, metastases, or both was performed in 6(8.2%), 9(9.6%), and 5(6.9%) of pts, respectively. The main grade (G) 3 -4 toxicities were: neutropenia (G3 21.9%, G4 15.1%), diarrhea (G3 17.8%, G4 1.4%), hypertension G3 (6.8%), fatigue G3 (6.8%), and febrile neutropenia G4 (4.1%). Conclusions: The primary endpoint ORR was met. These results show the preliminary efficacy and safety of NIV in combination with FOLOXIRI/BEV as first-line therapy in pts with mCRC RAS/BRAF mut. Also, promising activity was observed in MSS subgroup pts. These data support the conduction of phase III randomized-controlled study. Research Sponsor: Bayer, Bristol Myers-Squibb. Clinical trial information: NCT04072198." @default.
• W4286295054 created "2022-07-21" @default.
• W4286295054 creator A5002745641 @default.
• W4286295054 creator A5003014678 @default.
• W4286295054 creator A5008135397 @default.
• W4286295054 creator A5014770379 @default.
• W4286295054 creator A5014792832 @default.
• W4286295054 creator A5028136107 @default.
• W4286295054 creator A5028325185 @default.
• W4286295054 creator A5046559582 @default.
• W4286295054 creator A5049629149 @default.
• W4286295054 creator A5050187820 @default.
• W4286295054 creator A5066394827 @default.
• W4286295054 creator A5069420006 @default.
• W4286295054 creator A5074752423 @default.
• W4286295054 creator A5085217559 @default.
• W4286295054 creator A5087678289 @default.
• W4286295054 date "2022-06-01" @default.
• W4286295054 modified "2023-10-03" @default.
• W4286295054 title "Phase II study of nivolumab in combination with FOLFOXIRI/bevacizumab as first-line treatment in patients with advanced colorectal cancer RAS/BRAF mutated (mut): NIVACOR trial (GOIRC-03-2018)." @default.
• W4286295054 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.3509" @default.
• W4286295054 hasPublicationYear "2022" @default.
• W4286295054 type Work @default.
• W4286295054 citedByCount "6" @default.
• W4286295054 countsByYear W42862950542022 @default.
• W4286295054 countsByYear W42862950542023 @default.
• W4286295054 crossrefType "journal-article" @default.
• W4286295054 hasAuthorship W4286295054A5002745641 @default.
• W4286295054 hasAuthorship W4286295054A5003014678 @default.
• W4286295054 hasAuthorship W4286295054A5008135397 @default.
• W4286295054 hasAuthorship W4286295054A5014770379 @default.
• W4286295054 hasAuthorship W4286295054A5014792832 @default.
• W4286295054 hasAuthorship W4286295054A5028136107 @default.
• W4286295054 hasAuthorship W4286295054A5028325185 @default.
• W4286295054 hasAuthorship W4286295054A5046559582 @default.
• W4286295054 hasAuthorship W4286295054A5049629149 @default.
• W4286295054 hasAuthorship W4286295054A5050187820 @default.
• W4286295054 hasAuthorship W4286295054A5066394827 @default.
• W4286295054 hasAuthorship W4286295054A5069420006 @default.
• W4286295054 hasAuthorship W4286295054A5074752423 @default.
• W4286295054 hasAuthorship W4286295054A5085217559 @default.
• W4286295054 hasAuthorship W4286295054A5087678289 @default.
• W4286295054 hasConcept C121608353 @default.
• W4286295054 hasConcept C126322002 @default.
• W4286295054 hasConcept C141071460 @default.
• W4286295054 hasConcept C143998085 @default.
• W4286295054 hasConcept C197934379 @default.
• W4286295054 hasConcept C203092338 @default.
• W4286295054 hasConcept C2776694085 @default.
• W4286295054 hasConcept C2776999253 @default.
• W4286295054 hasConcept C2777701055 @default.
• W4286295054 hasConcept C2777802072 @default.
• W4286295054 hasConcept C2778375690 @default.
• W4286295054 hasConcept C2780030458 @default.
• W4286295054 hasConcept C2780259306 @default.
• W4286295054 hasConcept C2780962732 @default.
• W4286295054 hasConcept C31760486 @default.
• W4286295054 hasConcept C526805850 @default.
• W4286295054 hasConcept C535046627 @default.
• W4286295054 hasConcept C71924100 @default.
• W4286295054 hasConcept C90924648 @default.
• W4286295054 hasConceptScore W4286295054C121608353 @default.
• W4286295054 hasConceptScore W4286295054C126322002 @default.
• W4286295054 hasConceptScore W4286295054C141071460 @default.
• W4286295054 hasConceptScore W4286295054C143998085 @default.
• W4286295054 hasConceptScore W4286295054C197934379 @default.
• W4286295054 hasConceptScore W4286295054C203092338 @default.
• W4286295054 hasConceptScore W4286295054C2776694085 @default.
• W4286295054 hasConceptScore W4286295054C2776999253 @default.
• W4286295054 hasConceptScore W4286295054C2777701055 @default.
• W4286295054 hasConceptScore W4286295054C2777802072 @default.
• W4286295054 hasConceptScore W4286295054C2778375690 @default.
• W4286295054 hasConceptScore W4286295054C2780030458 @default.
• W4286295054 hasConceptScore W4286295054C2780259306 @default.
• W4286295054 hasConceptScore W4286295054C2780962732 @default.
• W4286295054 hasConceptScore W4286295054C31760486 @default.
• W4286295054 hasConceptScore W4286295054C526805850 @default.
• W4286295054 hasConceptScore W4286295054C535046627 @default.
• W4286295054 hasConceptScore W4286295054C71924100 @default.
• W4286295054 hasConceptScore W4286295054C90924648 @default.
• W4286295054 hasIssue "16_suppl" @default.
• W4286295054 hasLocation W42862950541 @default.
• W4286295054 hasOpenAccess W4286295054 @default.
• W4286295054 hasPrimaryLocation W42862950541 @default.
• W4286295054 hasRelatedWork W2014795358 @default.
• W4286295054 hasRelatedWork W2037724349 @default.
• W4286295054 hasRelatedWork W2050348440 @default.
• W4286295054 hasRelatedWork W2051540233 @default.
• W4286295054 hasRelatedWork W2066462266 @default.
• W4286295054 hasRelatedWork W2340695374 @default.
• W4286295054 hasRelatedWork W2545945608 @default.
• W4286295054 hasRelatedWork W3031852658 @default.
• W4286295054 hasRelatedWork W349909140 @default.
• W4286295054 hasRelatedWork W4286295054 @default.
• W4286295054 hasVolume "40" @default.
• W4286295054 isParatext "false" @default.
• W4286295054 isRetracted "false" @default.
• W4286295054 workType "article" @default.